health 68

Alzheimer's disease is a neurodegenerative disease that results in cognitive decline, and eventually death. In the brain, the disease causes neurons to die and break down, and involves high levels of a peptide called amyloid and aggregations of a protein called tau. However, scientists are coming to appreciate that inflammation may also play a role. "Alzheimer's brains usually contain evidence of neuroinflammation, and researchers increasingly think that this could be a possible driver of the disease, by causing neurons in the brain to degenerate," says David Emery, a researcher from the University of Bristol, and an author on the study, which was recently published in  Frontiers in Aging Neuroscience . So, what's causing this inflammation? Some genetic risk-factors for Alzheimer's disease can have effects on the inflammatory response, but infection may also play a role. " Neuroinflammation in the brain may be a reaction to the presence of bacteria...

The new methodology involves easily trapping proteins that bear a specific modification that can provide potential markers for conditions. The specific modification is based on sugar and when attached to a protein affects how the protein functions. Protein modification is a normal, carefully regulated cellular function, but in some instances this can go wrong. Alzheimer's, along with other conditions including cancers, type 2 diabetes, and cardio-vascular disease, is affected by dysregulation (abnormal or imperfect regulation) of these sugar modifications to proteins. Identifying such proteins is a key step in understanding their involvement in these various conditions. The newly developed methodology  could open the way for treatments that target these protein alterations, and ultimately the condition. Previously, capturing these proteins has been very difficult as the sugar modification was prone to falling off the protein. In order to capture them, researcher's req...

Beta-amyloid plaques from an AD mouse mannequin. Pink represents beta-amyloid deposits (plaques), brown represents microglia cells and blue/purple is nuclei of neurons and glial cells. Credit score: Stefan Prokop, MD, Perelman College of Drugs, College of Pennsylvania Three new gene variants, present in a genome extensive affiliation research of Alzheimer's illness (AD), level to the mind's immune cells within the onset of the dysfunction. These genes encode three proteins which might be present in microglia, cells which might be a part of the mind's damage response system. The research is a world collaboration of 4 AD analysis consortia that analyzed DNA from 85,000 topics. The outcomes are reported on-line this week in  Nature Genetics . Research of this kind give attention to figuring out new therapeutic targets for remedy or prevention of AD, a objective of researchers world-wide. Genetic variation of the sort described on this pap...

"We found that those who have non-elective (emergency or urgent) hospitalizations and who have not previously been diagnosed with dementia or Alzheimer's disease had a rapid decline in cognitive function (i.e., thinking abilities) compared to the prehospital rates," said Bryan James, PhD, an epidemiologist and in the Rush Alzheimer's Disease Center and an assistant professor in the Rush Department of Internal Medicine. "By comparison, people who were never hospitalized and those who had elective hospitalizations did not experience the drastic decline in cognitive function." James and colleagues presented the research data at the Alzheimer's Association International Conference in London on July 17. Study compares hospitalization data and cognitive assessments for 930 older adults The data emerged from a study of 930 older adults (75 percent female, an average age of 81 years old) enrolled in the Rush Memory and Aging Project (MAP) in Chicago. The...

The new finding, which builds on the team's previous work of identifying 24 susceptibility genes, enables a better understanding of the mechanisms underlying the disease and offers further hope in developing new treatments. Dr Rebecca Sims from Cardiff University's School of Medicine said: "In addition to identifying two genes that affect the risk of developing Alzheimer's disease, our new research reveals a number of other genes and proteins that form a network likely to be important in its development. These particular genes, which suggest that immune cells in the brain play a causal role in the disease, are also very good targets for potential drug treatment." Dr Rosa Sancho, Head of Research at Alzheimer's Research UK, added: "The discovery of new genes is like finding puzzle pieces that biologists can start to fit together to build a complete picture of a disease. "Alzheimer's Research UK is proud to be supporting scientists at the ...

Researchers have identified that tuning up the activity pathway of the DNA's natural repair toolkit -- which normally helps to restore breakages in our genetic material -- could help to prevent the death of nerve cells which trigger neurological diseases. Leading scientists from the University of Sheffield's Department of Molecular Biology and Biotechnology (MBB) and its Sheffield Institute of Translational Neuroscience (SITraN) examined the C9orf72 gene which contains six DNA nucleotides -- the building blocks of our DNA where all important cellular information is stored. When this series of nucleotides is expanded and repeated multiple times, neurodegenerative diseases can occur. The expansions of the gene forms genetic material called 'R-loops' which make the DNA vulnerable to breakages. They found that accumulation of R-loops and increased DNA breakage in neurons lead to neurodegenerative diseases. Our cells have their own repair toolkits specially designed...

A large-scale trial led by the University of Exeter, presented at the international Alzheimer's Association International Conference (AAIC) 2017 on Tuesday July 18, has found that cognitive rehabilitation leads to people seeing satisfying progress in areas that enable them to maintain their functioning and independence. Cognitive rehabilitation involves a therapist working with the person with dementia and a family carer to identify issues where they would like to see improvements. Together, they set up to three goals, and the therapist helps to develop strategies to achieve these goals. The research, funded by the National Institute for Health Research Health Technology Assessment programme, featured on the BBC's Horizon programme in May 2016. The goals participants chose were varied, as dementia affects people in a wide range of ways. Some participants wanted to find ways of staying independent, for example by learning or re-learning how to use household appliances or ...

Docosahexaenoic acid (DHA), a key essential Omega-3 fatty acid, produces signaling molecules called docosanoids in response to disruptions in the state of equilibrium within cells caused by injury or disease. Neuroprotectin D1 (NDP1) is a docosanoid that the Bazan lab discovered and found protects neurons by controlling which and how certain genes in the retina and brain respond. Research shows that the preclinical events in Alzheimer's disease including neuroinflammation, damage to dendritic spines -- small doorknob-shaped protrusions that help transmit electrical signals to the cell -- and problems with cell-to-cell communication coincide with decreased DHA content in the brain. The neuroprotective bioactivity of NPD1 includes inflammatory modulating properties as well as features that promote cell survival, both of which contribute to restoring a stable state of equilibrium, or homeostasis, within the cell. In experimental models of stroke, researchers at LSU Health New Or...

How one amino acid can spell the distinction between a wholesome growing old mind and early onset Alzheimer's illness. Credit score: Brian Kladko and Weihong Track/College of British Columbia The previous actual property adage about "location, location, location" may also apply to the biochemical genesis of Alzheimer's illness, based on new analysis from the College of British Columbia. Scientists had beforehand recognized a few essential steps within the formation of a protein known as amyloid beta, which accumulates in clumps, or "plaques," within the brains of individuals with Alzheimer's illness. These discoveries impressed efforts at disrupting the biochemical carving of amyloid beta's precursor protein into its last, poisonous form. The newest medication being examined attempt to silence an enzyme, known as BACE1, that cuts the precursor protein. However BACE1 has different capabilities which are useful, so...

Currently, the only way to detect amyloid beta in the brain is via PET scanning, which is expensive and not widely available, or a spinal tap, which is invasive and requires a specialized medical procedure. But now, a study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the blood have the potential to help identify people with altered levels of amyloid in their brains or cerebrospinal fluid. Ideally, a blood-based screening test would identify people who have started down the path toward Alzheimer's years before they could be diagnosed based on symptoms . "Our results demonstrate that this amyloid beta blood test can detect if amyloid has begun accumulating in the brain," said Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology and the study's senior author. "This is exciting because it could be the basis for a rapid and inexpensive blood screeni...